News from regado biosciences, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 23, 2010, 10:17 ET

Regado Biosciences to Present at the 22nd Annual Piper Jaffray Health Care Conference in New York City and the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference in San Francisco

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Nov 17, 2010, 10:30 ET

Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Nov 16, 2010, 11:45 ET

Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Nov 15, 2010, 12:00 ET
Nov 03, 2010, 10:32 ET

Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen...

Nov 03, 2010, 10:17 ET

Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control...

Nov 02, 2010, 19:30 ET

Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Oct 26, 2010, 10:17 ET

Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Sep 16, 2010, 10:17 ET

Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Sep 09, 2010, 10:17 ET

Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jul 27, 2010, 10:17 ET

Regado Biosciences to Present at the 2010 Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jul 26, 2010, 16:05 ET

Regado Biosciences Announces Publication in the American Heart Association Journal Circulation of the Results of a Phase 2a Study for the REG1 Anticoagulant System in Elective Percutaneous Interventions

Regado Biosciences, Inc., a privately held biopharmaceutical company pioneering the development of a novel two-component antithrombotic drug...

Jun 17, 2010, 09:30 ET

Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jun 08, 2010, 09:30 ET

Regado Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference in New York City on June 11, 2010

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jun 07, 2010, 09:30 ET

Regado Biosciences to Present at the 9th Annual Needham Healthcare Conference on June 10, 2010 in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

May 25, 2010, 09:30 ET

Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced...

Apr 30, 2010, 09:30 ET

Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that...

Apr 09, 2010, 09:30 ET

Regado Biosciences, Inc. Presents the First Clinical Experience with REG2, its Second Product Candidate, at the Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions in San Francisco, CA on April 9, 2010.

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Mar 15, 2010, 09:30 ET

Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010

Regado Biosciences, Inc.,  a privately held company leading the development of antithrombotic aptamers with active control agents, announced...

Dec 17, 2009, 10:17 ET

Regado Biosciences, Inc. Completes $40 Million Series D Financing

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents,...